		OIP		-			PTO/SB/0 She	8 (2-92) et 1 of 4	
Form PTO-1449 RR 2 6 7004			Docket Number: 04167	Docket Number: 041673/2043 Application Number: 09/620,174			174		
INFORMATION DISCLOSURE CITATION IN AN ARRIGONTION				Applicant: Tuszyns	Applicant: Tuszynski, et al.				
	(Us	se several sheeıs ij	(necessary)	Filing Date: 07/19/20	Filing Date: 07/19/2000 Group Art Unit: 1633				
			U.S. PA	TENT DOCUMENTS					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing D Approp		
F.D.	Al	01/21/92	5,082,670	Gage et al.		-			
	A2	06/25/96	5,529,774	Barba et al.					
	A3	07/22/97	5,650,148	Gage et al.					
	A4	11/04/97	5,683,695	Shen et al.					
٨	A5	05/26/98	5,756,312	Weiner et al.					
	A6	06/09/98	5,762,926	Gage et al.					
•			FOREIGN	PATENT DOCUMEN	ITS		-		
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO		
UX	A7 <b>,</b> ≰	06/28/90	WO 90/06757	PCT					
	•		·						
			OTHI	ER DOCUMENTS	(includ	ing author, title, D	ate, Pertinent P	ages, Etc.)	
Examiner Initials	Ref. No.	Title							
CX	A8. -≱€	Armelin et al., <u>70</u> :2702-6.	Armelin et al., "Pituitary extracts and steroid hormones in the control of 3T3 cell growth" Proc. Natl. Acad. Sci. (1973) 70:2702-6.						
1	A9 <sub></sub> ⊀			bin gene is enhanced by remot			· · ·	-308.	
	A10	Benoist et al.,	"In vivo sequence require	ments of the SV40 early prom	oter region" N	lature (1981) <u>290</u>	2:304-10.		
	A1i' *	274.	Ex vivo gene therapy for	Alzheimer's disease and spina	al cord injury"	Clinical Neuroso	<u>cience</u> (1996)	<u>3</u> :268-	
	A12€	Borsani et al.,	"cDNA sequence of hum	an beta-NGF" Nucleic Acids	<u>Res.</u> (1990) <u>18</u>	:4020.			
	A13 *	Breathnach et <u>50</u> :349-83.	al., "Organization and ex	pression of eucaryotic split gen	nes coding for	proteins" <u>Ann. R</u>	lev. Biochem.	(1981)	
	A14		Calcium phosphate-medial DNA" <u>BioTechniques</u> (19	ed gene transfer: a highly effic 988) <u>6</u> :632-8.	cient transfection	on system for sta	bly transformi	ng cells	
	A15.	Chen et al., "H	ligh-efficiency transforma	ation of mammalian cells by pl	asmid DNA"	Mol. Cell. Biol.	(1987) <u>7</u> :2745	-52.	
	A16		'umor necrosis factor-alph 990) <u>25</u> :161-170.	na induces mRNA for collagen	ase and TIMP	in human skin fi	broblasts" Co	nnect.	
V	A17/	Corner et al., "Distribution of NGF delivered into the rat CNS by either grafted NGF-secreting fibroblasts, intraparenchymal (IP) injections, or IP-infusions" Society for Neuroscience (1997) 23:53 Abstract 29.5.							

EXAMINER:

12/15 04 V18/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

APR 2 6 2004

INFORMATION SISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 041673/2043

Application Number: 09/620,174

Applicant: Tuszynski, et al.

Filing Date: 07/19/2000

Group Art Unit: 1633

		OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)
Examiner Initials	Ref. No.	Title
LDL	A18	Corden et al., "Promoter sequences of eukaryotic protein-coding genes." Science (1980) 209:1406-14.
	A19	DePamphilis et al., "Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals" <u>BioTechniques</u> (1988) <u>6</u> :662-80.
	A20	de Wet et al., "The mRNAs for the pro-alpha I(I) and pro-alpha 2(I) chains of type I procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady state ratios of the two mRNAs" J. Biol. Chem. (1983) 258:14385-9.
	A21 <b>x</b> €	Elias et al., "Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma" Ann. N.Y. Acad. Sci. (1990) 580:233-244.
	A22	Felgner et al., "Cationic liposome mediated transfection" Proc. West. Pharmacol. Soc. (1989) 32:115-21.
	A23	Felgner et al., "Cationic liposome mediated transfection" Focus. (1989) 11:21-25.
	A24	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure" Proc. Natl. Acad. Sci. (1987) 84:7413-7.
	A25	Fraley et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids" Trends Biochem. Sci. (1981) 6:77-80.
	A26*	Fromm et al., "Deletion mapping of DNA regions required for SV40 early region promoter function in vivo" <u>J. Mol. Appl. Genet.</u> (1982) <u>1</u> :457-81.
	A27	Gruss et al., "Simian virus 40 tandem repeated sequences as an element of the early promoter" Proc. Natl. Acad. Sci. (1981) 78:943-7.
	A28 <b>∱</b>	Hefti et al., "Nerve growth factor and Alzheimer's disease" Ann. Neurol. (1986) 20:275-81.
	A29 ∦	Higgins et al., "NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease" Exp. Neurol. (1989) 106:222-36.
	A30	Horellou et al., "Adenovirus-mediated gene transfer to the central nervous system for Parkinson's Disease" Experimental Neurobiology (1997) 144:131-8.
	A31x	Jolly et al., "Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene" Nucleic Acids Res. (1983) 11:1855-1872.
	A32. ★	Kobayashi et al., "Morphometric study on the CH\$ of the nucleus basalis of Meynert in Alzheimer's disease" Mol. Chem. Neuropathol. (1991) 15:193-206.
	A33*	Kordower et al., "The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor" Proc. Natl. Acad. Sci. (1994) 91:10898-10902.
	A34	Lehericy et al., "Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease" <u>J. Comp. Neurol.</u> (1993) 330:15-31.
V	A35 *	Levivier et al., "Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease" The Jo. Of Neuroscience (1995) 5:7810-20.
EVAMD		DATE CONCIDEDED: //a

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

APR 2 6 2004

Form PTO-1449

## INFORMATION DISCUSSIONE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 041673/2043 Application Number: 09/620,174

Applicant: Tuszynski, et al.

Filing Date: 07/19/2000 Group Art Unit: 1633

	•	OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)						
Examiner Initials	Ref. No.	Title .						
LDL	A36	Mannino et al., "Liposome mediated gene transfer" Biotechniques (1988) 6:682-90.						
	A37 <sup>^</sup>	Maxam et al., "Sequencing end-labeled DNA with base-specific chemical cleavages" Methods in Enzymology (1980) 65:499-560.						
	A384	McCutchan et al., "Enhancement of the infectivity of simian virus 40 deoxy ribonucleic acid with diethylaminoethyldextran" J. Natl. Cancer Inst. (1968) 41:351-7.						
	A39	Messing et al., "A system for shotgun DNA sequencing" Nucleic Acids Res. (1981) 9:309-21.						
,	A40 <sup>₹</sup>	Mesulam et al., "Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey." <u>J. Comp. Neurol.</u> (1983) <u>214</u> :170-197.						
	A41	Moreau et al., "The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants" Nucleic Acids Res. (1981) 9:6047-6068.						
	A42 ⊀	Mufson et al., "Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain" Exp. Neurol. (1989) 105:221-32.						
	A43 ★	Mufson et al., "Nerve growth factor receptor expressing human basal forebrain neurons: pathologic alterations in Alzheimer's and Parkinson's disease" <a href="Prog. Clin. Biol. Res.">Prog. Clin. Biol. Res.</a> (1989) <a href="317">317</a> :401-14.						
	A44 *	Palmer et al., "Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes" Proc. Natl. Acad. Sci. (1991) 88:1330-4.						
	A454	Potter et al., "Electroporation in biology: methods, applications, and instrumentation" Anal. Biochem. (1988) 174:361-73.						
	A46-	Prockop et al., "Heritable diseases of collagen" N. Eng. J. Med. (1984) 311:376-86.						
	A47*	Raymon et al., "Application of ex vivo gene therapy in the treatment of Parkinson's disease" Experimental Neurobiology (1997) 144:82-91.						
	A48*	Rossi et al., "Identification of a cell-specific transcriptional enhancer in the first intron of the mouse alpha 2 (type I) collagen gene" Proc. Natl. Acad. Sci. (1987) 84:5590-4.						
	A49	Schmidt et al., "Regulation of a collagen promoter by the product of viral mos oncogene" Nature (1985) 314:286-9.						
	A50*	Seliger et al., "Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription" <u>J. Virology</u> (1988) <u>62</u> :619-21.						
	A51 <b>¥</b>	Seliger et al., "Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level" <u>J. Immunol.</u> (1988) <u>141</u> :2138-44.						
	A52 <b>∜</b>	Shvaloff et al., "Lines of therapeutic research in Alzheimer's disease" Psychopharmacology Bulletin (1996) 32:343-52						
	A53	Smith et al., "Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy" <u>Proc. Natl. Acad. Sci.</u> (1999) <u>96</u> :10893-8.						
	A54*	Smith et al., "Characterization of collagen synthesized by normal and chemically transformed rat liver epithelial cell lines" <u>Bioghem.</u> (1980) 19:1820-5.						

**EXAMINER:** 

DATE CONSIDERED: //G/

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line in conformance and not considered. Include a copy of this form with next communication to applicant.

APR 2 & 2008 3

Form PTO-1449

## INFORMATION DESCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 041673/2043

Application Number: 09/620,174

Applicant: Tuszynski, et al.

Filing Date: 07/19/2000

Group Art Unit: 1633

		OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)
Examiner Initials	Ref. No.	Title
LIX	A55	Toneguzzo et al., "Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells" Molec. Cell. Biol. (1986) 6:703-6.
	A56≱	Tuszynski et al., "Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration" Gene Therapy (1996) 3:305-14.
	A57*	Tuszynski et al., "Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain" Ann Neurol. (1991) 30:625-36.
	A58,4	Tuszynski et al., "Somatic gene therapy for nervous system disease" <u>Ciba Foundation Symposium 196, Growth factors as drugs for neurological and sensory disorders</u> (1996) <u>196</u> :85-97.
	A59	Tuszynski et al., "The chronically injured spinal cord exhibits responsiveness to NGF delivered locally by gene therapy" <u>Society for Neuroscience</u> (1995) <u>21</u> :1562 Abstract 613.3.
	A60.4	Ullrich et al., "Human beta-nerve growth factor gene sequence highly homologous to that of a mouse" Nature (1983) 303:821-5.
	A61	Wolff et al., "Expression of retrovirally transduced genes in primary cultures of rat hepatocytes" Proc. Natl. Acad. Sci. (1987) 84:3344-8.
<del></del>		
	L	·

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Form PTO-1449 PES DEPARTMENT OF COMMERCE				ATTY. DOCKET NO.	SERIAL-NO.			
(MODIFIED) PATERS AND TRADEMARK OFFICE				041673-2043		09/620,174		
	1 .	2 6 2004 E		APPLICANT				
INFO		ON DISCLESSURE (	CITATION	Tu	szynski,	Mark H.		-
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	& TRANSMART		FILING DATE		GROUP AR	T UNIT	
	(Use se	everal sheets if necess	sary)	07/19/200	0		1633	
			U.S. PATEN	IT DOCUMENTS				
		200111517			<u> </u>		FILING	DATE
EXAMINER I	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	IF.	:
		HOMBER					APPRO	PRIATE
				·				
•		·					_	
•	<b> </b>							
						<del>                                     </del>		<del></del>
	<u>-</u> -					<del> </del>		
			EODEICH BAT	TENT DOCUMENTS	<u> </u>	<u> </u>	<u> </u>	
	T		POREIGIN PA	TENT DOCUMENTS	1	SUB-	TRANS	ATION
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
				· ·		<del>                                     </del>		
						+		
						-		
		·				<del> </del>		
<del> </del>		<u> </u>	· .	<del></del>		_1		
		OTHER DOCUM	IENTS (Including A	Author, Title, Date, Perti	inent Pages	, Etc.)		
101	<u> </u>		ovirus-Mediated tran	sduction with human glia	l cell line-deri	ved neurotrop	hic factor	gene
UX.	A1 X			hydropyridine-induced do earch Communications, <u>2</u>			m or mous	8 .
	<b>y</b>	<del> </del>			·····	<del></del>	ronal Mor	robology
. 1	A2 ^	and Gocnition in Age	cts of NGF-Secreting ed Primates," Soc. F	g Genetically Modified Cel or Neuroscience Abstract	s, <u>21(</u> 2):613.	8 (1995)	וטוואו ואווטונ	phology
·				<u></u>			<u> </u>	
	A3**	Yang, et al., "Gene TReview," Journal of		Nervous System Injury: Th	ne Use of Cat	ionic Liposom	es: An Inv	ited
						Ma Danie 1	3-4 U: V	
	A4 *	Zlokovic, et al., "Cell Systems and Delive	lular and Molecular N ry Methodologies for	Neurosurgery: Pathways F Gene Therapy of The Ce	rom Concept entral Nervous	τ το κeality – I s System." <i>Ne</i>	-aπ II: ved urosurgen	xor Yı
$\bot V$		<u>40(4):805-813 (1997</u>						
	,	1						
•		l. //				•		
EXAMINER	1//			DATE CONSIDER	ED			<del></del>
,	//h	1/24		1 1/19/8	5			
				her or not citation is				
		n citation if notin tion to applicant.	conformance and	d not considered. Inc	clude any o	opy of this	form wi	th next

5 070 4	110	LVC DEDARTING	OF COMMERCE	ATTY. DOCKET NO		SERIAL NO	Page 1	or 1
Form PTO-14		DATENT AND AR	ATEMARK OFFICE	041673	09/620,174			
(MODIFIED) PATENT AND THE			ADEMARK OFFICE	APPLICANT		L		<u> </u>
INF	ORMATI	ONDISCLOSURE			Tuszynski,	Mark H.		
	•	TRADEMA		FILING DATE		GROUP AR	T UNIT	
	(Use se	everal sheets if nece	ssary)	07/19/	2000		1633	
<del></del>				IT DOCUMENTS		<u> </u>		
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS		DATE F PRIATE
•	<u> </u>			······································		<del> </del>	·	. •
•	<del>                                     </del>							
<del></del>				·				
				·				
	•		FOREIGN PAT	ENT DOCUMENTS	S			•
•	REF	DOCUMENT	DATE	COUNTRY ·	CLASS	SUB-	TRANS	LATION
	KEF	NUMBER			· · · · · · · · · · · · · · · · · · ·	CLASS	YES	NO
	<u> -</u>	· .	··.					
<u>.</u>								
	<u> </u>	·				<u> </u>		
		OTHER DOCU	MENTS (Including A	uthor, Title, Date, F	Pertinent Pages,	Etc.)		
LOL	ATX	Tuszynski, et al., Forebrain for 3 Mo No. EN986956 1-10	Fargeted Intraparenchy nths Does Not Acceler (1998).	/mal Delivery of Huma ate β-Amyloid Plaque	an NGF by Gene Disposition," <i>Exp</i>	Transfer to th perimental Ne	e Primate urology, A	Basal rticle
				<del></del>			<del></del>	<del></del>
<del></del>					<del></del>			<del></del>
				· · · · · · · · · · · · · · · · · · ·		<del></del>	<del></del>	<del></del>
<del></del>	<u> </u>				······································			<del></del>
-						· · · · · · · · · · · · · · · · · · ·		
		1					<del></del>	
		1				•		
EXAMINER			7	DATE CONSIDE	ERED			
			considered, wheth					
			conformance and	not considered.	Include any co	ppy of this	form wit	h next
		citation if not in tion to applicant.	conformance and	not considered.	Include any co	ppy of this	form wit	h nex